Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Petros PharmaceuticalsPTPI Cash Ratio is 1.66 as of Mar. 2026, which is 68% above its 10-year median of 0.99. Among 974 Drug Manufacturers companies, Petros Pharmaceuticals ranks better than 74.33% on this metric.
Petros Pharmaceuticals has a Cash Ratio of 1.66. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Petros Pharmaceuticals's Cash Ratio or its related term are showing as below:
PTPI'
s Cash Ratio Range Over the Past 10 Years
Min: 0.05 Med: 0.99 Max: 2.48
Current: 1.66
During the past 7 years, Petros Pharmaceuticals's highest Cash Ratio was 2.48. The lowest was 0.05. And the median was 0.99.
PTPI's Cash Ratio is ranked better than 74.33% of 974
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs PTPI: 1.66
Petros Pharmaceuticals (OTCPK:PTPI) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petros Pharmaceuticals Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Petros Pharmaceuticals's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petros Pharmaceuticals (PTPI) has a Cash Ratio of 1.66 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Petros Pharmaceuticals and its competitors. This is 68% above median its historical median of 0.99. Over the past decade, Petros Pharmaceuticals' Cash Ratio has ranged from 0.05 to 2.48. According to the industry distribution chart, Petros Pharmaceuticals ranks #250 out of 974 companies in the Drug Manufacturers industry, placing it in the top 25.7%.
Is Petros Pharmaceuticals' Cash Ratio too high?
Petros Pharmaceuticals' current Cash Ratio of 1.66 is 68% above median its 10-year median of 0.99. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 2.48. The Drug Manufacturers industry median Cash Ratio is 0.61. Petros Pharmaceuticals' value of 1.66 is 172.1% above this industry median. Based on the distribution chart, Petros Pharmaceuticals ranks #250 out of 974 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Petros Pharmaceuticals' Cash Ratio compare to STEK and KOAN?
According to the Drug Manufacturers industry distribution chart, Petros Pharmaceuticals ranks #250 out of 974 companies for Cash Ratio. This puts Petros Pharmaceuticals in the upper half of its industry. The industry median Cash Ratio is 0.61. Petros Pharmaceuticals' value of 1.66 is 172.1% above this benchmark. Historically, Petros Pharmaceuticals' own Cash Ratio has ranged from 0.05 to 2.48 over the past decade. While the company's 10-year median is 0.99 vs. the industry median of 0.61, Petros Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.61, based on 974 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Petros Pharmaceuticals's current Cash Ratio of 1.66 is 172.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Petros Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petros Pharmaceuticals's current Cash Ratio is 1.66, which is 68% above median its own 10-year median of 0.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current Cash Ratio of 1.66. The current Cash Ratio is 1.66, which is 68% above median its 10-year median of 0.99 and 172.1% above the Drug Manufacturers industry median of 0.61. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current Cash Ratio is 1.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTPI has been successfully added to your 
